Your browser doesn't support javascript.
loading
Effects of Adaptive Servo-Ventilation on Quality of Life: The READ-ASV Registry.
Arzt, Michael; Munt, Oliver; Pépin, Jean-Louis; Heinzer, Raphael; Kübeck, Raphaela; von Hehn, Ulrike; Ehrsam-Tosi, Daniela; Benjafield, Adam V; Woehrle, Holger.
Afiliação
  • Arzt M; Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
  • Munt O; ResMed Science Centre, Martinsried, Germany.
  • Pépin JL; University Grenoble Alpes, Laboratoire HP2, U1300 Inserm, CHU Grenoble Alpes, Grenoble, France.
  • Heinzer R; Centre d'Investigation et de Recherche sur le Sommeil, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Kübeck R; The Clinical Research Institute GmbH, Munich, Germany.
  • von Hehn U; Medistat GmbH, Krummwisch, Germany.
  • Ehrsam-Tosi D; ResMed Science Centre, Basel, Switzerland.
  • Benjafield AV; ResMed Science Center, Sydney, New South Wales, Australia; and.
  • Woehrle H; Sleep and Ventilation Center Blaubeuren, Ulm, Germany.
Ann Am Thorac Soc ; 21(4): 651-657, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38241012
ABSTRACT
Rationale Adaptive servo-ventilation (ASV) effectively treats sleep-disordered breathing, including central sleep apnea (CSA) and coexisting obstructive sleep apnea (OSA).

Objectives:

The prospective, multicenter European READ-ASV (Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with Adaptive Servo-Ventilation) registry investigated the effects of first-time ASV therapy on disease-specific quality of life (QoL).

Methods:

The registry enrolled adults with CSA with or without OSA who had ASV therapy prescribed between September 2017 and March 2021. The primary endpoint was change in disease-specific QoL (Functional Outcomes of Sleep Questionnaire [FOSQ]) score between baseline and 12-month follow-up. Sleepiness determined using the Epworth Sleepiness Scale (ESS) score was a key secondary outcome. For subgroup analysis, participants were classified as symptomatic (FOSQ score < 17.9 and/or ESS score > 10) or asymptomatic (FOSQ score ⩾ 17.9 and/or ESS score ⩽ 10).

Results:

A total of 801 individuals (age, 67 ± 12 yr; 14% female; body mass index, 31 ± 5 kg/m2; apnea-hypopnea index, 48 ± 22/h) were enrolled; analyses include those with paired baseline and follow-up data. After 12 ± 3 months on ASV, median (interquartile range) FOSQ score had increased significantly from baseline (+0.8 [-0.2 to 2.2]; P < 0.001; n = 499). This was due to a significantly increased FOSQ score in symptomatic participants (+1.69 [0.38 to 3.05]), with little change in asymptomatic individuals (+0.11 [-0.39 to 0.54]). The median ESS score also improved significantly from baseline during ASV (-2.0 [-5.0 to 0.0]; P < 0.001).

Conclusions:

ASV treatment of CSA with or without coexisting OSA was associated with improvements in disease-specific QoL and daytime sleepiness, especially in individuals with sleep-disordered breathing symptoms before therapy initiation. These improvements in patient-reported outcomes support the use of ASV in this population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes da Apneia do Sono / Apneia do Sono Tipo Central / Apneia Obstrutiva do Sono / Insuficiência Cardíaca Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes da Apneia do Sono / Apneia do Sono Tipo Central / Apneia Obstrutiva do Sono / Insuficiência Cardíaca Idioma: En Ano de publicação: 2024 Tipo de documento: Article